Abstract
Heart Failure is the only cardiovascular disease diagnosis increasing in prevalence in the United States. Currently there are more than 5 million people diagnosed with heart failure in the United States and that population is increasing exponentially. Clinical trials in advanced pharmacological therapies have shown a significant value in reducing the morbidity and mortality of the disease process. Nevertheless, many patients who are optimally treated with drug therapy continue to progress from asymptomatic left ventricular dysfunction to symptomatic and then end-stage heart failure. Beyond drug therapy, devices have begun to make a significant impact on symptoms and clinical outcomes in patients, particularly those with more advanced forms of heart failure. New technologies being investigated include destination and bridge LV assist devices. Due to the invasive nature of these devices a new generation of “less invasive” percutaneous devices are now being studied. These new generation devices offer the promise of improved LV function and an enhanced neurohormonal profile for the failing ventricle, thus improving the quality of life in the ever-burgeoning heart failure population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Heart Association (2004) Heart disease and stroke statistics: 2004 update. American Heart Association, Dallas, TX
Berry C, Murdoch DR, McMurray JJ (2001) Economics of chronic heart failure. Eur J Heart Fail 3:283–291
Aronow WS, Ahn C, Kronzon I, Koenigsberg M (1991) Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 67:295–299
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303–310
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. carvedilol heart failure study group. N Engl J Med 334:1349–1355
Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321
Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Flemming T (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594–1602
Mancini D, Burkhoff D (2005) Mechanical device-based methods of managing and treating heart failure. Circulation 112:438–448
Costanzo MR (2006) Ultrafiltration versus IV diuretics for patients hospitalized for acute decompensated congestive heart failure: a prospective randomized clinical trial: UNLOAD. Presented at the American College of Cardiology annual scientific session, March 2006
Haithcock BE, Morita H, Fanous NH, Suzuki G, Sabbah HN (2004) Hemodynamic unloading of the failing left ventricle using an arterial-to-arterial extracorporeal flow circuit. Ann Thorac Surg 77:158–163
Konstam MA, Czerska B, Bohm M, Oren RM, Sadowski J, Khanal S, Abraham WT, Wasler A, Dahm JB, Gavazzi A, Gradinac S, Legrand V, Mohacsi P, Poelzl G, Radovancevic B, Van Bakel AM, Zile MR, Cabua B, Bartus K, Jansen P (2005) Continuous aortic flow augmentation: hemodynamic and renal responses to a novel percutaneous intervention in patients with decompensated heart failure. Circulation 112:3107–3114
Gharib M, Beizaie M (2003) Correlation between negative near-wall shear stress in human aorta and various stages of congestive heart failure. Ann Biomed Eng 3:678–685
Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G (2001) Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 104:2917–2922
LaRocca GM, Shimbo D, Rodriguez CJ, Stewart A, Naka Y, Weinberger J, Homma S, Pizzarello R (2006) The impella recover LP 5.0 left ventricular assist device: a bridge to coronary artery bypass grafting and cardiac transplantation. J Am Soc Echocardiogr Apr;19(4):468.e5–7
Henriques JP, Remmelink M, Baan J Jr, van der Schaaf RJ, Vis MM, Koch KT, Scholten EW, de Mol BA, Tijssen JG, Piek JJ, de Winter RJ (2006) Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol, Apr 1;97(7):990–992, Epub 2006 Feb 13
Registry. ABVW (1999) Courtesy of Abiomed Inc
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mather, P.J., Konstam, M.A. Newer mechanical devices in the management of acute heart failure. Heart Fail Rev 12, 167–172 (2007). https://doi.org/10.1007/s10741-007-9018-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-007-9018-1